A Novel Platform Technology of Targeted Degradation of Transmembrane Proteins
- Explore how Fudan University has established an endocytosis-independent TPD technology for transmembrane proteins
- Discuss how the technology achieved pM-nM DC50 and >90% Dmax for PD-L1 by small molecule degraders
- Assess how it also achieved significantly better efficacy in vivo than clinical PD-L1 antibodies